Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy

Aitziber Buqué, Norma Bloy, Fernando Aranda, Isabelle Cremer, Alexander Eggermont, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Eric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

49 Citaten (Scopus)


Progressing malignancies establish robust immunosuppressive networks that operate both systemically and locally. In particular, as tumors escape immunosurveillance, they recruit increasing amounts of myeloid and lymphoid cells that exert pronounced immunosuppressive effects. These cells not only prevent the natural recognition of growing neoplasms by the immune system, but also inhibit anticancer immune responses elicited by chemo-, radio- and immuno therapeutic interventions. Throughout the past decade, multiple strategies have been devised to counteract the accumulation or activation of tumor-infiltrating immunosuppressive cells for therapeutic purposes. Here, we review recent preclinical and clinical advances on the use of small molecules that target the immunological tumor microenvironment for cancer therapy. These agents include inhibitors of indoleamine 2,3-dioxigenase 1 (IDO1), prostaglandin E2, and specific cytokine receptors, as well as modulators of intratumoral purinergic signaling and arginine metabolism.

Originele taal-2Engels
Nummer van het tijdschrift6
StatusGepubliceerd - 2 jun. 2016
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy'. Samen vormen ze een unieke vingerafdruk.

Citeer dit